Ensysce enrolls first patient in final phase of PF614-MPAR-102 overdose-protection trial

Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC

0.00
  • Ensysce Biosciences initiated the final stage of its PF614-MPAR-102 clinical study, enrolling the first patient to evaluate MPAR overdose-protection technology.
  • Earlier clinical data have already been presented, showing the drug maintained therapeutic exposure at prescribed use while limiting exposure under excessive oral dosing.
  • The final-stage readout is expected in the future, aiming to confirm the protective effect across a broader set of dosing scenarios.
  • Program positioning centers on an opioid designed to curb overdose risk without relying on traditional abuse-deterrent approaches, supporting a potential differentiated safety label.
  • The study is supported by the National Institute on Drug Abuse, which could reduce development cost and bolster external validation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.